Key Highlights
- Makana Therapeutics discovers a fourth gene in pigs that will reduce organ rejection in human transplants.
- The fourth gene knockout builds upon their existing Triple Knockout Pig (TKO) technology.
- Clinical trials in xenotransplantation are planned for early 2026 pending FDA approval.
- Research collaboration with the University of Miami advanced this discovery.
Source: Business Wire
Notable Quotes
- “We have discovered an additional human immune system response responsible for early xenograft organ failure.” — Joe Tector, MD, PhD, FACS, Founder at Makana
- “Our sole focus is to restore an entirely normal life to every patient with organ failure.” — Mark Platt, CEO at Makana Therapeutics
SoHC's Take
Makana Therapeutics’ discovery of the fourth gene knockout represents a significant leap forward in the field of xenotransplantation, particularly for kidney failure patients. By addressing early immune rejection mechanisms, this breakthrough holds potential to transform the current landscape of organ transplants, offering new hope to the thousands on the waiting list. If the upcoming clinical trials are successful, this advancement could mark a pivotal moment in the drive to alleviate the global organ shortage crisis.
